1.37
price down icon9.87%   -0.15
after-market After Hours: 1.36 -0.01 -0.73%
loading
Erasca Inc stock is traded at $1.37, with a volume of 2.55M. It is down -9.87% in the last 24 hours and up +0.00% over the past month.
See More
Previous Close:
$1.52
Open:
$1.49
24h Volume:
2.55M
Relative Volume:
1.85
Market Cap:
$439.06M
Revenue:
-
Net Income/Loss:
$-125.04M
P/E Ratio:
-1.6707
EPS:
-0.82
Net Cash Flow:
$-122.99M
1W Performance:
-8.05%
1M Performance:
+0.00%
6M Performance:
-49.82%
1Y Performance:
-33.50%
1-Day Range:
Value
$1.36
$1.49
1-Week Range:
Value
$1.36
$1.61
52-Week Range:
Value
$1.27
$3.45

Erasca Inc Stock (ERAS) Company Profile

Name
Name
Erasca Inc
Name
Phone
(858) 465-6511
Name
Address
10835 ROAD TO THE CURE, SUITE 140, SAN DIEGO
Name
Employee
0
Name
Twitter
Name
Next Earnings Date
Name
Latest SEC Filings
Name
ERAS's Discussions on Twitter

Compare ERAS with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
ERAS
Erasca Inc
1.37 439.06M 0 -125.04M -122.99M -0.82
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.82 131.41B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
634.23 72.26B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
591.87 36.10B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
270.02 35.03B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
272.17 28.24B 3.81B -644.79M -669.77M -6.24

Erasca Inc Stock (ERAS) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-26-25 Initiated Raymond James Outperform
Nov-18-24 Initiated Jefferies Buy
Mar-11-24 Initiated CapitalOne Overweight
Jan-05-24 Downgrade BofA Securities Buy → Neutral
Oct-11-23 Initiated H.C. Wainwright Buy
Mar-30-23 Initiated Mizuho Buy
Feb-24-23 Initiated Goldman Buy
Feb-03-23 Upgrade Morgan Stanley Equal-Weight → Overweight
View All

Erasca Inc Stock (ERAS) Latest News

pulisher
Mar 30, 2025

Erasca (NASDAQ:ERAS) Coverage Initiated by Analysts at Raymond James - MarketBeat

Mar 30, 2025
pulisher
Mar 30, 2025

Erasca, Inc. (NASDAQ:ERAS) Shares Bought by Swiss National Bank - Defense World

Mar 30, 2025
pulisher
Mar 27, 2025

Erasca (NASDAQ:ERAS) Now Covered by Analysts at Raymond James - Defense World

Mar 27, 2025
pulisher
Mar 26, 2025

Raymond James sets $5 target for Erasca stock, cites valuation gap By Investing.com - Investing.com South Africa

Mar 26, 2025
pulisher
Mar 26, 2025

Raymond James Initiates Coverage of Erasca (ERAS) with Outperform Recommendation - Nasdaq

Mar 26, 2025
pulisher
Mar 26, 2025

This Spotify Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga

Mar 26, 2025
pulisher
Mar 26, 2025

Raymond James sets $5 target for Erasca stock, cites valuation gap - Investing.com India

Mar 26, 2025
pulisher
Mar 26, 2025

Raymond James Initiates Erasca at Outperform With $5 Price Target - MarketScreener

Mar 26, 2025
pulisher
Mar 26, 2025

Erasca initiated with an Outperform at Raymond James - TipRanks

Mar 26, 2025
pulisher
Mar 26, 2025

Charles Schwab Investment Management Inc. Buys 39,066 Shares of Erasca, Inc. (NASDAQ:ERAS) - Defense World

Mar 26, 2025
pulisher
Mar 25, 2025

Erasca Announces Three Poster Presentations at the 2025 AACR Annual Meeting - The Manila Times

Mar 25, 2025
pulisher
Mar 25, 2025

Game-Changing Cancer Treatments: Erasca Reveals 3 Novel Drug Breakthroughs at AACR 2025 - Stock Titan

Mar 25, 2025
pulisher
Mar 24, 2025

Bank of New York Mellon Corp Grows Holdings in Erasca, Inc. (NASDAQ:ERAS) - Defense World

Mar 24, 2025
pulisher
Mar 24, 2025

What is HC Wainwright’s Estimate for Erasca FY2029 Earnings? - Defense World

Mar 24, 2025
pulisher
Mar 23, 2025

The Goldman Sachs Group Has Lowered Expectations for Erasca (NASDAQ:ERAS) Stock Price - Defense World

Mar 23, 2025
pulisher
Mar 23, 2025

Erasca (NASDAQ:ERAS) Earns “Buy” Rating from HC Wainwright - Defense World

Mar 23, 2025
pulisher
Mar 21, 2025

Erasca, Inc. Reports 2024 Financial and Strategic Progress - TipRanks

Mar 21, 2025
pulisher
Mar 20, 2025

Erasca Inc. (ERAS) reports earnings - Quartz

Mar 20, 2025
pulisher
Mar 20, 2025

ERASCA Earnings Results: $ERAS Reports Quarterly Earnings - Nasdaq

Mar 20, 2025
pulisher
Mar 20, 2025

Erasca, Inc. SEC 10-K Report - TradingView

Mar 20, 2025
pulisher
Mar 20, 2025

Erasca Reports Fourth Quarter and Full Year 2024 Business Updates and Financial Results - The Manila Times

Mar 20, 2025
pulisher
Mar 20, 2025

Erasca's $440M War Chest Powers Two Groundbreaking Cancer Drugs Into 2025 Trials - StockTitan

Mar 20, 2025
pulisher
Mar 19, 2025

Erasca (ERAS) Expected to Announce Earnings on Wednesday - Defense World

Mar 19, 2025
pulisher
Mar 10, 2025

Brokerages Set Erasca, Inc. (NASDAQ:ERAS) Price Target at $5.70 - Defense World

Mar 10, 2025
pulisher
Mar 09, 2025

Morgan Stanley Reaffirms Overweight Rating for Erasca (NASDAQ:ERAS) - Defense World

Mar 09, 2025
pulisher
Mar 08, 2025

Rhumbline Advisers Boosts Stock Holdings in Erasca, Inc. (NASDAQ:ERAS) - Defense World

Mar 08, 2025
pulisher
Mar 07, 2025

Erasca’s Promising Oncology Advances: Buy Rating Backed by Strong Market Potential and Competitive Edge - TipRanks

Mar 07, 2025
pulisher
Mar 07, 2025

Erasca, Inc. (NASDAQ:ERAS) Shares Acquired by New York State Common Retirement Fund - Defense World

Mar 07, 2025
pulisher
Feb 28, 2025

Erasca stock hits 52-week low at $1.32 amid market challenges - Investing.com Australia

Feb 28, 2025
pulisher
Feb 25, 2025

Erasca Inc Still Hasn’t Convinced Analysts? - Stocks Register

Feb 25, 2025
pulisher
Feb 20, 2025

Erasca stock hits 52-week low at $1.5 amid market challenges - Investing.com Australia

Feb 20, 2025
pulisher
Feb 19, 2025

Erasca stock hits 52-week low at $1.5 amid market challenges By Investing.com - Investing.com South Africa

Feb 19, 2025
pulisher
Feb 17, 2025

Metastatic Pancreatic Cancer Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail

Feb 17, 2025
pulisher
Feb 10, 2025

Investor’s Toolkit: Key Ratios for Assessing Erasca Inc (ERAS)’s Performance - The Dwinnex

Feb 10, 2025
pulisher
Feb 07, 2025

Erasca Inc’s: Contrasting Stock Performances in a Volatile Market - The InvestChronicle

Feb 07, 2025
pulisher
Feb 07, 2025

Erasca Inc [ERAS] Records 200-Day SMA of $2.5522 - Knox Daily

Feb 07, 2025
pulisher
Feb 06, 2025

Pyxis Oncology Inc [PYXS] stock for 174,364 USD was acquired by Connealy Pamela Ann - Knox Daily

Feb 06, 2025
pulisher
Feb 06, 2025

BlackBerry Ltd [BB] Records 200-Day SMA of $2.77 - Knox Daily

Feb 06, 2025
pulisher
Feb 06, 2025

Erasca (NASDAQ:ERAS) Stock Price Down 6.1%What's Next? - MarketBeat

Feb 06, 2025
pulisher
Feb 04, 2025

Metric Deep Dive: Understanding Erasca Inc (ERAS) Through its Ratios - The Dwinnex

Feb 04, 2025
pulisher
Feb 04, 2025

Erasca Inc (ERAS) is a good investment, but the stock may be undervalued - US Post News

Feb 04, 2025
pulisher
Feb 03, 2025

Erasca (NASDAQ:ERAS) Trading Up 6.6%Time to Buy? - MarketBeat

Feb 03, 2025
pulisher
Jan 31, 2025

Erasca to Present at the Guggenheim Securities SMID Cap Biotech Conference - The Manila Times

Jan 31, 2025
pulisher
Jan 31, 2025

Erasca to Present at the Guggenheim Securities SMID Cap Biotech Conference - GlobeNewswire Inc.

Jan 31, 2025
pulisher
Jan 28, 2025

Erasca: Future 'Streamlined' But Still Uncertain (NASDAQ:ERAS) - Seeking Alpha

Jan 28, 2025
pulisher
Jan 27, 2025

What Are You Thinking About Investing In Erasca Inc (NASDAQ: ERAS) Stock? - Stocks Register

Jan 27, 2025
pulisher
Jan 27, 2025

Erasca’s Naporafenib Is Shaping Up Nicely For NRASm Melanoma (NASDAQ:ERAS) - Seeking Alpha

Jan 27, 2025
pulisher
Jan 22, 2025

Down -25.4% in 4 Weeks, Here's Why You Should You Buy the Dip in Erasca (ERAS) - MSN

Jan 22, 2025
pulisher
Jan 21, 2025

Erasca (NASDAQ:ERAS) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance

Jan 21, 2025
pulisher
Jan 20, 2025

Down -27.17% in 4 Weeks, Here's Why Erasca (ERAS) Looks Ripe for a Turnaround - MSN

Jan 20, 2025
pulisher
Jan 17, 2025

Down -24.08% in 4 Weeks, Here's Why You Should You Buy the Dip in Erasca (ERAS) - MSN

Jan 17, 2025

Erasca Inc Stock (ERAS) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$70.69
price down icon 1.05%
$76.29
price down icon 2.18%
$31.13
price down icon 0.77%
$19.29
price down icon 5.07%
$91.06
price down icon 4.10%
biotechnology ONC
$272.17
price up icon 1.79%
Cap:     |  Volume (24h):